Key result
Immature platelet fraction shows promise as a non-invasive biomarker for evaluating thrombocytopenia and predicting outcomes.
Why the study?
Reticulated platelets reflect megakaryopoiesis activity and may have clinical utility beyond thrombocytopenia and post-transplantation, but an overview of their diagnostic and prognostic applications is needed.
Are reticulated or immature platelet assays useful as a diagnostic or prognostic tool in patients with thrombocytopenia or undergoing chemotherapy/stem cell transplantation?
Are reticulated or immature platelet assays useful as a diagnostic or prognostic tool in patients with thrombocytopenia or undergoing chemotherapy/stem cell transplantation?
Immature platelet fraction is a useful non-invasive biomarker for diagnosing thrombocytopenia and monitoring bone marrow recovery, though its utility in other conditions requires further research.
Reticulated platelets are immature platelets circulating in blood; they reflect the activity of megakaryopoiesis in the bone marrow.Therefore, they can be used as a non-invasive test in patients with thrombocytopenia in various clinical conditions.Reticulated or immature platelet assays are useful for the differential diagnosis of thrombocytopenia and for monitoring bone marrow recovery after chemotherapy or stem cell transplantation and several other clinical entities.The concentration of retPLT in bone marrow is on the average 2-3 times higher than in peripheral blood, where they correlate with megakaryocyte numbers.The platelets persist in the circulation for 7-10 days, retPLT have a much shorter lifespan ( < 1 day).Therefore they can act as a marker of megakaryopoietic activity in the bone marrow which gives retPLT clinical and diagnostic utility.This review provides an overview of the clinical conditions in which reticulated platelets or immature platelets can be considered as a diagnostic tool or prognostic tool.This overview also indicates that more research is needed before reticulated or immature platelet assays can be applied in other clinical conditions than thrombocytopenia and after transplantation.
No takes yet. Share an insight, caveat, or question.
Kavitha Thilak Abin Varghese (2023) conducted a review in Various clinical entities (Thrombocytopenia, COVID-19, Dengue, Sepsis, CAD, Liver diseases, Preeclampsia). Immature Platelet Fraction (IPF) measurement was evaluated. Immature platelet fraction is a promising non-invasive biomarker for evaluating megakaryopoietic activity and predicting outcomes in conditions like thrombocytopenia, dengue, sepsis, and COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: